Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLH12016
- Development stage
- Phase 2
- Lead developer
- Qilu Pharmaceutical
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Oral
01
Overview
QLH12016 is an investigational small molecule drug developed by Qilu Pharmaceutical for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is currently in phase 1 clinical trials, where its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity are being evaluated. The precise mechanism of action has not been publicly disclosed; however, some sources suggest it may target SMARCA2 and could be a PROTAC (proteolysis-targeting chimera) degrader. The drug is administered orally and is being studied primarily in China[1][2][4][6].
- Other names
- QLH12016QLH-12016QLH 12016
02
Targets
CRBN (Cereblon)
Beyond the preview
Go deeper on QLH12016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLH12016.